Akebia Therapeutics (AKBA) Financials

$3.63 +0.01 (+0.28%)

Closing price 07/7/2025 04:00 PM Eastern

Extended Trading

$3.66 +0.03 (+0.83%)

As of 07/7/2025 07:57 PM Eastern

Annual Income Statements for Akebia Therapeutics

This table shows Akebia Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-124	-61	-136	-74	-144	-280	-385	-282	-94	-52	-69
Consolidated Net Income / (Loss)	-37	-61	-136	-74	-144	-280	-385	-282	-94	-52	-69
Net Income / (Loss) Continuing Operations	-37	-61	-136	-74	-144	-280	-385	-282	-94	-52	-69
Total Pre-Tax Income	-38	-61	-136	-74	-172	-286	-385	-282	-94	-52	-69
Total Operating Income	-38	-62	-136	-77	-178	-286	-378	-265	-81	-46	-50
Total Gross Profit	0.00	0.00	1.54	181	200	190	-1.83	61	207	120	97
Total Revenue	0.00	0.00	1.54	181	208	335	295	212	292	195	160
Operating Revenue	0.00	0.00	1.54	181	208	335	295	212	292	195	160
Total Cost of Revenue	0.00	0.00	0.00	0.00	7.77	145	296	151	86	74	63
Operating Cost of Revenue	-	-	0.00	-	7.77	145	296	151	86	74	63
Total Operating Expenses	38	62	138	258	378	476	376	325	288	167	147
Selling, General & Admin Expense	15	18	22	27	87	149	154	174	139	100	107
Research & Development Expense	23	43	116	231	291	323	218	148	130	63	38
Other Operating Expenses / (Income)	-	-	0.00	-	0.07	3.53	3.41	3.49	3.18	3.24	3.22
Restructuring Charge	-	-	-	-	-	-	0.00	0.00	16	0.18	0.06
Total Other Income / (Expense), net	0.21	0.51	0.71	3.00	6.24	-0.00	-7.02	-18	-13	-5.67	-19
Interest Expense	-	-	-	-	-	-	0.00	0.00	0.91	0.00	0.52
Interest & Investment Income	0.21	0.51	0.90	2.80	6.15	0.79	-8.87	-20	-16	-6.03	-18
Other Income / (Expense), net	-	-	-0.19	0.20	0.08	-0.79	1.86	2.41	3.15	0.36	-0.24
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	-	-	-	-	-	-	0.00	-	0.00
Basic Earnings per Share	($8.04)	($2.29)	($3.60)	($1.69)	($2.47)	($2.36)	($2.78)	($1.70)	($0.52)	($0.28)	($0.33)
Weighted Average Basic Shares Outstanding	15.41M	26.47M	37.72M	43.50M	58.04M	118.40M	138.46M	165.95M	182.78M	187.47M	210.95M
Diluted Earnings per Share	($8.04)	($2.29)	($3.60)	($1.69)	($2.47)	($2.36)	($2.78)	($1.70)	($0.52)	($0.28)	($0.33)
Weighted Average Diluted Shares Outstanding	15.41M	26.47M	37.72M	43.50M	58.04M	118.40M	138.46M	165.95M	182.78M	187.47M	210.95M
Weighted Average Basic & Diluted Shares Outstanding	15.41M	26.47M	37.72M	43.50M	58.04M	118.40M	138.46M	181.23M	184.25M	209.37M	236.23M

This table shows Akebia Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-54	-6.07	-27	-11	-14	0.61	-18	-8.58	-20	-23	6.11
Consolidated Net Income / (Loss)	-54	-1.91	-27	-11	-14	0.61	-18	-8.58	-20	-23	6.11
Net Income / (Loss) Continuing Operations	-54	-1.91	-27	-11	-14	0.61	-18	-8.58	-20	-23	6.11
Total Pre-Tax Income	-55	-0.33	-27	-11	-14	0.61	-18	-8.58	-20	-23	6.11
Total Operating Income	-50	-4.87	-26	-9.00	-13	1.37	-15	-8.73	-13	-14	14
Total Gross Profit	10	112	20	39	24	38	21	27	23	26	50
Total Revenue	49	117	40	56	42	56	33	44	37	46	57
Operating Revenue	49	117	40	56	42	56	33	44	37	46	57
Total Cost of Revenue	38	5.58	20	17	18	19	12	17	14	20	7.63
Operating Cost of Revenue	38	5.58	20	17	18	19	12	17	14	20	7.63
Total Operating Expenses	61	109	45	48	37	36	36	35	36	40	36
Selling, General & Admin Expense	32	30	25	27	23	25	25	27	27	28	26
Research & Development Expense	28	76	20	20	13	9.87	9.73	7.65	8.49	12	9.75
Other Operating Expenses / (Income)	0.74	1.54	0.57	0.95	0.86	0.86	0.71	0.76	0.77	0.98	0.70
Restructuring Charge	0.18	1.22	0.11	-0.09	0.17	-	0.06	0.00	0.00	-	0.00
Total Other Income / (Expense), net	-4.86	-3.55	-1.28	-2.18	-1.45	-0.76	-3.05	0.14	-7.53	-8.50	-7.40
Interest Expense	0.91	-	0.00	0.00	0.00	-	0.52	0.00	0.00	-	0.00
Interest & Investment Income	-3.95	-6.70	-1.56	-1.64	-1.41	-1.42	-2.50	-2.15	-6.66	-6.88	-7.77
Other Income / (Expense), net	-	-	0.28	-0.53	-0.04	0.66	-0.03	2.29	-0.87	-1.62	0.37
Basic Earnings per Share	($0.29)	($0.04)	($0.15)	($0.06)	($0.08)	$0.01	($0.09)	($0.04)	($0.10)	($0.10)	$0.03
Weighted Average Basic Shares Outstanding	183.88M	182.78M	184.77M	186.82M	188.31M	187.47M	204.96M	209.71M	210.35M	210.95M	235.50M
Diluted Earnings per Share	($0.29)	($0.03)	($0.15)	($0.06)	($0.08)	$0.01	($0.09)	($0.04)	($0.10)	($0.10)	$0.03
Weighted Average Diluted Shares Outstanding	183.88M	182.78M	184.77M	186.82M	188.31M	187.47M	204.96M	209.71M	210.35M	210.95M	241.60M
Weighted Average Basic & Diluted Shares Outstanding	183.96M	184.25M	0.00	188.31M	188.39M	209.37M	209.60M	210.29M	218.18M	236.23M	262.64M

This table details how cash moves in and out of Akebia Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	12	17	138	-117	36	43	81	-79	-59	-49	8.97
Net Cash From Operating Activities	-27	-52	58	-56	-97	-257	-110	-253	-73	-23	-41
Net Cash From Continuing Operating Activities	-27	-52	58	-56	-97	-257	-110	-253	-73	-23	-41
Net Income / (Loss) Continuing Operations	-37	-61	-136	-74	-144	-280	-385	-282	-94	-52	-69
Consolidated Net Income / (Loss)	-37	-61	-136	-74	-144	-280	-385	-282	-94	-52	-69
Depreciation Expense	0.05	0.10	0.30	0.62	0.90	2.25	2.08	1.93	1.65	1.59	1.46
Amortization Expense	0.27	0.56	0.49	0.61	0.29	36	33	36	36	40	40
Non-Cash Adjustments To Reconcile Net Income	6.01	4.71	6.13	12	8.89	86	254	83	52	8.18	25
Changes in Operating Assets and Liabilities, net	3.22	2.94	187	4.01	36	-102	-14	-92	-68	-21	-38
Net Cash From Investing Activities	-65	-14	13	-177	37	211	-40	40	-0.11	0.00	-0.03
Net Cash From Continuing Investing Activities	-65	-14	13	-177	37	211	-40	40	-0.11	0.00	-0.03
Purchase of Property, Plant & Equipment	-0.23	-0.41	-2.66	-1.62	-1.61	-6.66	-0.32	-0.06	-0.11	0.00	-0.03
Net Cash From Financing Activities	104	83	67	116	97	89	232	134	15	-25	50
Net Cash From Continuing Financing Activities	104	83	67	116	97	89	232	134	15	-25	50
Repayment of Debt	-	-	-	-	0.00	-15	0.00	0.00	-33	-32	-38
Issuance of Debt	0.24	0.01	0.02	0.01	0.02	78	20	0.00	-	0.00	45
Issuance of Common Equity	104	83	67	115	96	26	211	89	7.53	6.79	43
Other Financing Activities, net	0.00	0.13	0.12	1.31	0.65	0.13	1.23	45	40	0.00	0.39
Cash Interest Paid	-	-	-	-	-	0.78	7.84	9.63	6.76	6.06	5.04

This table details how cash moves in and out of Akebia Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	0.87	-55	-34	-4.37	-7.12	-3.60	-0.96	-2.46	-5.47	18	62
Net Cash From Operating Activities	34	-55	-18	3.63	-7.17	-2.31	-19	-10	-6.70	-4.47	-14
Net Cash From Continuing Operating Activities	34	-55	-18	3.63	-7.17	-2.31	-19	-10	-6.70	-4.47	-14
Net Income / (Loss) Continuing Operations	-54	-6.07	-27	-11	-14	0.61	-18	-8.58	-20	-23	6.11
Consolidated Net Income / (Loss)	-54	-6.07	-27	-11	-14	0.61	-18	-8.58	-20	-23	6.11
Depreciation Expense	0.41	0.41	0.40	0.40	0.40	0.39	0.36	0.40	0.36	0.34	0.31
Amortization Expense	9.01	8.72	9.01	9.01	9.01	13	9.01	9.01	9.01	13	0.00
Non-Cash Adjustments To Reconcile Net Income	22	12	3.76	2.92	1.09	0.42	3.59	3.48	12	5.96	9.71
Changes in Operating Assets and Liabilities, net	57	-70	-3.83	2.48	-3.17	-17	-14	-14	-7.66	-1.16	-30
Net Cash From Investing Activities	-	-	0.00	-	-	-	0.00	-0.03	-0.00	-0.00	0.15
Net Cash From Continuing Investing Activities	-	-	0.00	-	-	-	0.00	-0.03	-0.00	-0.00	0.15
Purchase of Property, Plant & Equipment	-	-	-	-	-	-	0.00	-	-0.00	-0.00	-0.02
Sale of Property, Plant & Equipment	-	-	-	-	-	-	0.00	-	-	-	0.17
Net Cash From Financing Activities	-33	-0.00	-16	-8.00	0.05	-1.29	18	7.64	1.22	22	75
Net Cash From Continuing Financing Activities	-33	-0.00	-16	-8.00	0.05	-1.29	18	7.64	1.22	22	75
Repayment of Debt	-33	-	-16	-8.00	-	-8.00	-37	-0.37	-0.52	0.00	-0.53
Issuance of Debt	-	-	0.00	-	-	-	37	8.00	-	-	10
Issuance of Common Equity	0.06	-0.00	0.03	-	0.05	6.71	19	-	1.75	22	65
Other Financing Activities, net	-	-	0.00	-	-	0.00	0.14	0.01	-	0.23	0.48

This table presents Akebia Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	111	143	300	364	997	771	644	529	356	242	221
Total Current Assets	110	141	296	358	468	310	371	271	185	118	114
Cash & Equivalents	33	50	187	70	105	147	229	150	90	43	52
Accounts Receivable	-	0.00	34	34	17	39	27	52	40	39	34
Inventories, net	-	-	-	0.00	114	116	61	37	22	16	16
Prepaid Expenses	1.56	2.56	2.16	6.35	16	6.63	15	33	33	20	11
Plant, Property, & Equipment, net	0.21	0.54	2.61	3.62	8.02	10	8.62	6.75	5.21	3.63	2.20
Total Noncurrent Assets	0.31	1.38	1.28	2.27	520	451	264	251	166	120	105
Goodwill	-	-	-	0.00	55	55	55	59	59	59	59
Other Noncurrent Operating Assets	0.31	1.38	1.28	2.27	137	105	65	84	35	25	46
Total Liabilities & Shareholders' Equity	111	143	300	364	997	771	644	529	356	242	221
Total Liabilities	6.92	12	232	242	361	376	397	455	351	272	270
Total Current Liabilities	6.89	12	114	141	266	208	187	261	130	100	81
Accounts Payable	2.02	2.31	2.04	7.00	43	39	41	34	18	15	15
Accrued Expenses	4.86	9.56	30	52	151	129	131	109	76	68	63
Current Deferred Revenue	-	0.00	82	82	57	40	15	21	3.74	-	0.00
Other Current Liabilities	-	-	-	-	-	-	-	-	-	0.00	2.27
Total Noncurrent Liabilities	0.03	0.07	118	101	95	168	209	194	221	172	189
Long-Term Debt	-	-	-	-	-	76	96	0.00	34	17	39
Other Noncurrent Operating Liabilities	0.03	0.01	0.03	0.02	30	59	88	173	144	112	150
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	104	131	68	123	636	395	248	74	5.23	-31	-49
Total Preferred & Common Equity	104	131	68	123	636	395	248	74	5.23	-31	-49
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	104	131	68	123	636	395	248	74	5.23	-31	-49
Common Stock	205	293	365	494	1,151	1,189	1,425	1,537	1,562	1,578	1,629
Retained Earnings	-101	-161	-297	-371	-514	-794	-1,178	-1,463	-1,557	-1,609	-1,678
Accumulated Other Comprehensive Income / (Loss)	-0.06	-0.23	-0.04	-0.44	-0.26	0.00	0.01	0.01	0.01	0.01	0.01

This table presents Akebia Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	530	436	281	254	235	225	220	207	310
Total Current Assets	308	238	121	118	110	113	112	100	204
Cash & Equivalents	0.00	145	0.00	54	47	42	39	34	113
Accounts Receivable	82	23	19	20	23	27	30	32	62
Inventories, net	40	40	20	21	18	26	24	20	20
Prepaid Expenses	0.00	30	25	24	22	19	19	13	9.14
Plant, Property, & Equipment, net	0.00	5.62	0.00	4.42	4.02	3.27	2.90	2.53	1.90
Total Noncurrent Assets	59	193	59	131	121	109	105	104	104
Goodwill	59	55	59	59	59	59	59	59	59
Other Noncurrent Operating Assets	0.00	57	0.00	18	17	23	28	36	45
Total Liabilities & Shareholders' Equity	530	436	281	254	235	225	220	207	310
Total Liabilities	471	422	300	281	274	253	254	258	286
Total Current Liabilities	237	188	88	92	80	66	107	66	91
Accounts Payable	0.00	20	0.00	12	9.04	12	10	13	13
Accrued Expenses	95	87	51	56	63	54	54	52	71
Current Deferred Revenue	0.00	1.27	0.00	0.00	0.00	0.70	43	-	1.24
Other Current Liabilities	0.00	14	0.00	-	-	-	-	-	5.99
Total Noncurrent Liabilities	75	234	17	188	195	186	147	192	194
Long-Term Debt	0.00	-	0.00	18	35	30	38	38	47
Other Noncurrent Operating Liabilities	75	191	17	127	117	113	109	153	148
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-1,497	14	-1,584	-27	-39	-27	-34	-50	25
Total Preferred & Common Equity	59	14	-19	-27	-39	-27	-34	-50	25
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-1,497	14	-1,584	-27	-39	-27	-34	-50	25
Common Stock	0.00	1,559	0.00	1,568	1,570	1,600	1,602	1,605	1,697
Retained Earnings	-1,497	-1,545	-1,584	-1,595	-1,610	-1,627	-1,636	-1,656	-1,672
Accumulated Other Comprehensive Income / (Loss)	0.00	0.01	0.00	0.01	0.01	0.01	0.01	0.01	0.01

This table displays calculated financial ratios and metrics derived from Akebia Therapeutics' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	11,706.32%	14.63%	61.26%	-12.05%	-28.17%	38.19%	-33.46%	-17.70%
EBITDA Growth	-166.41%	-61.76%	-123.23%	44.62%	-135.09%	-40.91%	-36.94%	34.33%	82.05%	89.94%	-122.54%
EBIT Growth	-154.92%	-62.13%	-122.14%	44.04%	-132.88%	-61.21%	-30.96%	30.29%	70.38%	40.88%	-10.49%
NOPAT Growth	-138.12%	-62.13%	-121.84%	43.81%	-132.36%	-60.69%	-31.97%	29.99%	69.46%	42.74%	-9.11%
Net Income Growth	-181.26%	-63.95%	-123.58%	45.73%	-94.90%	-94.76%	-37.61%	26.72%	66.59%	44.89%	-33.67%
EPS Growth	93.67%	71.52%	-57.21%	53.06%	-46.15%	4.45%	-17.80%	38.85%	69.41%	46.15%	-17.86%
Operating Cash Flow Growth	-142.53%	-90.69%	210.49%	-196.98%	-73.60%	-164.06%	57.12%	-129.16%	71.08%	68.03%	-73.88%
Free Cash Flow Firm Growth	-151.46%	-71.96%	320.67%	-156.78%	-1,181.10%	70.12%	91.28%	-677.93%	88.12%	18.71%	7.21%
Invested Capital Growth	-168.83%	-54.05%	-2,478.10%	-1.56%	268.68%	-1.95%	-76.68%	-71.12%	-188.08%	-102.66%	-60.62%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	96.55%	-12.88%	2.98%	-4.39%	0.78%	25.66%	-23.93%	-5.71%
EBITDA Q/Q Growth	-12.74%	-18.39%	-15.38%	41.28%	-141.69%	1.23%	2.60%	9.86%	61.14%	73.29%	-232.36%
EBIT Q/Q Growth	-13.14%	-18.14%	-15.35%	40.87%	-142.64%	-1.89%	2.58%	8.34%	45.04%	12.58%	-54.83%
NOPAT Q/Q Growth	-13.14%	-18.14%	-15.19%	40.71%	-142.75%	-1.68%	2.10%	7.50%	42.81%	11.89%	-45.06%
Net Income Q/Q Growth	-13.56%	-18.52%	-15.29%	42.02%	-111.13%	-14.04%	1.56%	6.16%	41.90%	4.63%	-50.91%
EPS Q/Q Growth	84.82%	-106.62%	-9.42%	46.52%	-133.02%	5.60%	6.08%	10.99%	41.57%	12.50%	-50.00%
Operating Cash Flow Q/Q Growth	-18.52%	-35.43%	195.43%	-200.48%	-142.69%	-7.71%	35.72%	-14.50%	10.00%	69.13%	-5.61%
Free Cash Flow Firm Q/Q Growth	0.00%	-38.89%	359.67%	-164.40%	-1,832.08%	74.70%	76.99%	-28.98%	-132.06%	78.22%	45.46%
Invested Capital Q/Q Growth	-2.45%	38.15%	-217.14%	15.06%	232.99%	0.29%	-39.91%	-19.96%	70.51%	10.41%	-35.38%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	100.00%	96.26%	56.62%	-0.62%	28.81%	70.74%	61.90%	60.56%
EBITDA Margin	0.00%	0.00%	-8,850.68%	-41.52%	-85.15%	-74.40%	-115.84%	-105.90%	-13.76%	-2.08%	-5.62%
Operating Margin	0.00%	0.00%	-8,889.90%	-42.31%	-85.76%	-85.46%	-128.23%	-124.97%	-27.62%	-23.77%	-31.51%
EBIT Margin	0.00%	0.00%	-8,902.15%	-42.20%	-85.72%	-85.70%	-127.60%	-123.83%	-26.54%	-23.58%	-31.66%
Profit (Net Income) Margin	0.00%	0.00%	-8,843.45%	-40.65%	-69.12%	-83.48%	-130.61%	-133.25%	-32.22%	-26.68%	-43.33%
Tax Burden Percent	98.14%	99.53%	100.00%	100.00%	83.52%	97.68%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	99.46%	99.17%	99.34%	96.34%	96.54%	99.72%	102.36%	107.61%	121.37%	113.14%	136.88%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	-186.04%	-61.46%	-132.85%	-381.53%	-4,361.38%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	-180.00%	-19.58%	-34.27%	-295.26%	-4,263.06%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	148.18%	7.19%	13.03%	206.16%	4,123.55%	0.00%	0.00%
Return on Equity (ROE)	-54.93%	-51.66%	-136.35%	-77.27%	-37.86%	-54.27%	-119.82%	-175.37%	-237.83%	409.60%	174.03%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-197.16%	-59.49%	-8.50%	-271.17%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	-61.67%	-23.02%	-26.17%	-32.48%	-53.13%	-44.67%	-17.54%	-15.36%	-21.93%
Return on Assets (ROA)	0.00%	0.00%	-61.26%	-22.17%	-21.10%	-31.64%	-54.38%	-48.07%	-21.28%	-17.37%	-30.02%
Return on Common Equity (ROCE)	9.37%	-51.66%	-136.35%	-77.27%	-37.86%	-54.27%	-119.82%	-175.37%	-237.83%	409.60%	174.03%
Return on Equity Simple (ROE_SIMPLE)	-35.58%	-46.35%	-199.28%	-60.10%	-22.58%	-70.84%	-155.42%	-381.07%	-1,801.64%	169.78%	141.12%
Net Operating Profit after Tax (NOPAT)	-27	-43	-96	-54	-125	-200	-264	-185	-57	-32	-35
NOPAT Margin	0.00%	0.00%	-6,222.93%	-29.62%	-60.03%	-59.82%	-89.76%	-87.48%	-19.33%	-16.64%	-22.06%
Net Nonoperating Expense Percent (NNEP)	-14.81%	-14.28%	-20.17%	-6.92%	-6.05%	-41.88%	-98.58%	-86.27%	-98.33%	-119.80%	-318.22%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-789.93%	336.74%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	3.74%	43.38%	100.62%	71.19%	29.26%	38.10%	39.44%
SG&A Expenses to Revenue	0.00%	0.00%	1,446.91%	14.90%	41.91%	44.61%	52.30%	82.28%	47.39%	51.50%	66.52%
R&D to Revenue	0.00%	0.00%	7,543.00%	127.41%	140.08%	96.41%	74.15%	69.86%	44.44%	32.41%	23.51%
Operating Expenses to Revenue	0.00%	0.00%	8,989.90%	142.31%	182.02%	142.08%	127.61%	153.78%	98.36%	85.67%	92.07%
Earnings before Interest and Taxes (EBIT)	-38	-62	-137	-76	-178	-287	-376	-262	-78	-46	-51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-38	-61	-136	-75	-177	-249	-341	-224	-40	-4.05	-9.01
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.27	3.02	5.86	5.73	0.50	1.90	1.63	5.34	20.30	0.00	0.00
Price to Tangible Book Value (P/TBV)	2.27	3.02	5.86	5.73	1.25	15.50	8.36	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	259.91	3.88	1.52	2.24	1.37	1.87	0.36	1.20	2.59
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.03	2.11	3.09	15.78	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	90.30	2.13	0.04	2.03	0.79	1.62	0.28	1.16	2.51
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	2.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	1.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.02	0.19	0.39	1.32	12.63	-1.13	-0.79
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.19	0.39	0.00	6.52	-0.56	-0.79
Financial Leverage	-1.05	-1.05	-2.00	-3.03	-0.82	-0.37	-0.38	-0.70	-0.97	1.29	0.27
Leverage Ratio	1.08	1.08	2.23	3.48	1.79	1.72	2.20	3.65	11.17	-23.58	-5.80
Compound Leverage Factor	1.07	1.07	2.21	3.36	1.73	1.71	2.26	3.93	13.56	-26.68	-7.93
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	2.30%	16.11%	28.02%	56.86%	92.67%	846.13%	-368.79%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	2.30%	0.00%	0.00%	56.86%	44.88%	426.93%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	16.11%	28.02%	0.00%	47.79%	419.20%	-368.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	97.70%	83.89%	71.98%	43.14%	7.33%	-746.13%	468.79%
Debt to EBITDA	0.00	0.00	0.00	0.00	-0.08	-0.30	-0.28	-0.44	-1.64	-8.57	-4.30
Net Debt to EBITDA	0.00	0.00	0.00	0.00	1.73	0.29	0.50	0.23	0.61	2.04	1.46
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.30	-0.28	0.00	-0.85	-4.25	-4.30
Debt to NOPAT	0.00	0.00	0.00	0.00	-0.12	-0.38	-0.36	-0.53	-1.17	-1.07	-1.10
Net Debt to NOPAT	0.00	0.00	0.00	0.00	2.46	0.36	0.65	0.28	0.43	0.25	0.37
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-0.38	-0.36	0.00	-0.60	-0.53	-1.10
Altman Z-Score	19.26	17.97	-1.12	0.84	-0.34	-0.88	-3.07	-4.56	-5.65	-8.54	-9.58
Noncontrolling Interest Sharing Ratio	117.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	16.05	11.88	2.59	2.54	1.76	1.49	1.98	1.04	1.43	1.18	1.41
Quick Ratio	15.82	11.67	2.57	2.49	1.27	0.90	1.58	0.77	1.01	0.82	1.07
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-24	-40	89	-51	-649	-194	-17	-132	-16	-13	-12
Operating Cash Flow to CapEx	-12,001.31%	-12,658.70%	2,175.28%	-3,462.33%	-6,070.61%	-3,868.38%	-34,822.71%	-428,754.24%	-64,170.18%	0.00%	-123,209.09%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-17.26	0.00	-22.81
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-80.74	0.00	-78.64
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-80.87	0.00	-78.71
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.01	0.55	0.31	0.38	0.42	0.36	0.66	0.65	0.69
Accounts Receivable Turnover	0.00	0.00	0.00	5.33	8.17	12.07	8.97	5.40	6.37	4.89	4.35
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	1.26	3.34	3.09	2.94	3.98	3.96
Fixed Asset Turnover	0.00	0.00	0.97	58.19	35.69	36.41	31.01	27.53	48.88	44.02	54.96
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.31	3.54	7.36	4.02	3.32	4.54	4.24
Days Sales Outstanding (DSO)	0.00	0.00	0.00	68.52	44.70	30.25	40.70	67.63	57.32	74.62	83.92
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	289.56	109.18	118.27	124.12	91.70	92.25
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	1,169.85	102.98	49.57	90.72	110.07	80.37	86.13
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	68.52	-1,125.15	216.83	100.32	95.19	71.37	85.95	90.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-4.84	-7.46	-192	-195	329	323	75	22	-19	-39	-62
Invested Capital Turnover	0.00	0.00	-0.02	-0.94	3.10	1.03	1.48	4.36	225.60	-6.71	-3.17
Increase / (Decrease) in Invested Capital	-3.04	-2.62	-185	-3.00	525	-6.42	-248	-54	-41	-20	-24
Enterprise Value (EV)	128	257	139	385	8.90	680	232	343	82	225	401
Market Capitalization	237	396	399	703	316	752	405	395	106	234	415
Book Value per Share	$5.12	$4.28	$1.78	$2.59	$11.15	$3.32	$1.71	$0.42	$0.03	($0.16)	($0.23)
Tangible Book Value per Share	$5.12	$4.28	$1.78	$2.59	$4.43	$0.41	$0.33	($0.53)	($0.68)	($0.67)	($0.50)
Total Capital	104	131	68	123	651	471	344	172	71	4.10	-10
Total Debt	0.00	0.00	0.00	0.00	15	76	96	98	66	35	39
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	76	96	0.00	34	17	39
Net Debt	-109	-138	-260	-318	-307	-72	-172	-52	-24	-8.24	-13
Capital Expenditures (CapEx)	0.23	0.41	2.66	1.62	1.61	6.66	0.32	0.06	0.11	0.00	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.32	-9.31	-78	-101	-104	-46	-84	-42	-2.82	-7.15	-19
Debt-free Net Working Capital (DFNWC)	104	129	182	217	218	101	184	108	88	36	33
Net Working Capital (NWC)	104	129	182	217	203	101	184	10	56	18	33
Net Nonoperating Expense (NNE)	10	18	40	20	19	79	120	97	38	20	34
Net Nonoperating Obligations (NNO)	-109	-138	-260	-318	-307	-72	-172	-52	-24	-8.24	-13
Total Depreciation and Amortization (D&A)	0.32	0.65	0.79	1.23	1.19	38	35	38	37	42	42
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-5,100.33%	-55.48%	-50.09%	-13.81%	-28.64%	-19.92%	-0.96%	-3.67%	-11.83%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	11,860.13%	119.88%	104.74%	30.27%	62.55%	50.86%	29.97%	18.38%	20.55%
Net Working Capital to Revenue	0.00%	0.00%	11,860.13%	119.88%	97.52%	30.27%	62.55%	4.77%	19.03%	9.39%	20.55%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($8.04)	($2.29)	($3.60)	($1.77)	($2.47)	($2.36)	($2.77)	($1.70)	($0.51)	($0.28)	($0.33)
Adjusted Weighted Average Basic Shares Outstanding	20.37M	37.94M	38.83M	48.35M	117.12M	129.86M	153.50M	165.95M	182.78M	187.47M	210.95M
Adjusted Diluted Earnings per Share	($8.04)	($2.29)	($3.60)	($1.77)	($2.47)	($2.36)	($2.77)	($1.70)	($0.51)	($0.28)	($0.33)
Adjusted Weighted Average Diluted Shares Outstanding	20.37M	37.94M	38.83M	48.35M	117.12M	129.86M	153.50M	165.95M	182.78M	187.47M	210.95M
Adjusted Basic & Diluted Earnings per Share	($8.04)	($2.29)	($3.60)	($1.77)	($2.47)	($2.36)	($2.77)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	15.41M	26.47M	37.72M	43.50M	58.04M	118.40M	138.46M	181.23M	184.25M	209.37M	236.23M
Normalized Net Operating Profit after Tax (NOPAT)	-27	-43	-96	-54	-125	-200	-264	-185	-45	-32	-35
Normalized NOPAT Margin	0.00%	0.00%	-6,222.93%	-29.62%	-60.03%	-59.82%	-89.76%	-87.48%	-15.52%	-16.57%	-22.03%
Pre Tax Income Margin	0.00%	0.00%	-8,843.45%	-40.65%	-82.76%	-85.46%	-130.61%	-133.25%	-32.22%	-26.68%	-43.33%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-85.69	0.00	-98.08
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-62.41	0.00	-68.34
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-85.81	0.00	-98.15
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-62.54	0.00	-68.40
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Akebia Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-0.09%	103.56%	0.00%	-55.39%	-13.69%	-52.13%	-18.49%	-22.58%	-10.98%	-17.26%	75.84%
EBITDA Growth	8.88%	107.69%	68.29%	-100.28%	91.04%	267.90%	64.82%	2,520.33%	-9.04%	-115.23%	353.73%
EBIT Growth	7.44%	92.49%	57.51%	-127.97%	74.05%	141.72%	40.87%	32.50%	-2.29%	-884.20%	192.73%
NOPAT Growth	8.16%	92.55%	57.04%	-118.48%	74.14%	140.29%	41.65%	3.01%	4.07%	-829.37%	229.26%
Net Income Growth	9.15%	97.27%	60.28%	-137.94%	73.22%	132.08%	33.08%	23.18%	-38.30%	-3,826.14%	133.98%
EPS Growth	14.71%	92.50%	57.14%	-140.00%	72.41%	133.33%	40.00%	33.33%	-25.00%	-1,100.00%	133.33%
Operating Cash Flow Growth	160.08%	12.94%	18.88%	111.84%	-121.20%	95.78%	-10.80%	-377.38%	6.59%	-93.50%	30.08%
Free Cash Flow Firm Growth	-4.80%	379.70%	-475.61%	-7.92%	-154.08%	-43.89%	179.79%	-120.30%	80.40%	-35.74%	-80.01%
Invested Capital Growth	-339.04%	-188.08%	272.62%	-425.07%	33.29%	-102.66%	-171.00%	7.05%	-6.29%	-60.62%	-8.21%
Revenue Q/Q Growth	-61.45%	141.01%	-65.93%	40.92%	-25.42%	33.65%	-41.98%	33.86%	-14.25%	24.23%	23.31%
EBITDA Q/Q Growth	-194.21%	110.38%	-473.82%	99.23%	-2,885.37%	526.31%	-143.82%	153.21%	-234.50%	40.46%	695.47%
EBIT Q/Q Growth	-247.92%	90.34%	-420.03%	62.35%	-37.24%	115.53%	-1,190.31%	57.03%	-107.96%	-19.05%	187.16%
NOPAT Q/Q Growth	-203.55%	90.34%	-425.82%	64.86%	-44.91%	115.05%	-861.49%	41.58%	-43.32%	-14.40%	234.95%
Net Income Q/Q Growth	-283.69%	96.47%	-1,308.60%	58.43%	-29.69%	104.22%	-3,038.73%	52.28%	-133.50%	-13.80%	126.80%
EPS Q/Q Growth	-293.33%	89.66%	-400.00%	60.00%	-33.33%	112.50%	-1,000.00%	55.56%	-150.00%	0.00%	130.00%
Operating Cash Flow Q/Q Growth	210.26%	-261.75%	67.93%	120.69%	-297.49%	67.80%	-741.94%	48.20%	33.49%	33.29%	-204.23%
Free Cash Flow Firm Q/Q Growth	21.03%	-34.04%	-379.56%	141.26%	-171.09%	168.43%	297.58%	-110.49%	31.36%	324.41%	23.67%
Invested Capital Q/Q Growth	-657.27%	70.51%	387.28%	-168.85%	-14.37%	10.41%	-0.64%	9.86%	-30.79%	-35.38%	32.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	21.42%	95.25%	49.53%	69.34%	57.17%	66.78%	64.41%	60.94%	62.16%	56.20%	86.70%
EBITDA Margin	-84.13%	3.62%	-39.76%	-0.22%	-8.73%	27.86%	-17.16%	6.82%	-10.70%	-5.13%	24.76%
Operating Margin	-103.47%	-4.15%	-63.98%	-15.96%	-31.00%	2.44%	-45.81%	-19.99%	-33.41%	-30.77%	23.57%
EBIT Margin	-103.47%	-4.15%	-63.28%	-16.90%	-31.11%	3.61%	-45.91%	-14.74%	-35.74%	-34.25%	24.21%
Profit (Net Income) Margin	-111.05%	-1.63%	-67.18%	-19.82%	-34.46%	1.09%	-55.16%	-19.66%	-53.54%	-49.04%	10.66%
Tax Burden Percent	97.89%	578.18%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	109.64%	6.78%	106.17%	117.23%	110.78%	30.13%	120.14%	133.41%	149.79%	143.18%	44.03%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-654.77%	-1,286.39%	0.00%	0.00%	0.00%	-752.14%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-658.69%	-1,286.96%	0.00%	0.00%	0.00%	-753.07%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	637.13%	1,296.54%	0.00%	0.00%	0.00%	760.53%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-214.80%	-17.64%	10.15%	12.35%	425.87%	409.60%	8.39%	133.56%	102.41%	174.03%	3,385.36%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-217.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-46.40%	-2.74%	-51.15%	-11.33%	-23.72%	2.35%	-33.95%	-10.85%	-27.47%	-23.73%	16.72%
Return on Assets (ROA)	-49.79%	-1.07%	-54.30%	-13.28%	-26.28%	0.71%	-40.78%	-14.48%	-41.14%	-33.98%	7.36%
Return on Common Equity (ROCE)	-214.80%	-17.64%	10.15%	12.35%	425.87%	409.60%	8.39%	133.56%	102.41%	174.03%	3,385.36%
Return on Equity Simple (ROE_SIMPLE)	-1,170.72%	0.00%	279.38%	350.85%	138.11%	0.00%	157.88%	119.82%	91.25%	0.00%	-184.34%
Net Operating Profit after Tax (NOPAT)	-35	-3.41	-18	-6.30	-9.13	1.37	-10	-6.11	-8.75	-10	14
NOPAT Margin	-72.43%	-2.90%	-44.79%	-11.17%	-21.70%	2.44%	-32.06%	-13.99%	-23.39%	-21.54%	23.57%
Net Nonoperating Expense Percent (NNEP)	-19.93%	3.91%	0.57%	0.65%	-12.97%	-4.66%	0.93%	-39.42%	5,374.05%	-119.42%	-18.82%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	33.50%	-	-	-	95.45%	19.01%
Cost of Revenue to Revenue	78.58%	4.75%	50.47%	30.66%	42.83%	33.22%	35.59%	39.06%	37.84%	43.80%	13.30%
SG&A Expenses to Revenue	65.46%	25.47%	62.62%	47.96%	54.01%	45.26%	78.01%	61.67%	70.85%	59.52%	44.90%
R&D to Revenue	57.54%	64.67%	49.21%	35.83%	31.70%	17.56%	29.84%	17.52%	22.68%	25.35%	17.01%
Operating Expenses to Revenue	124.89%	92.50%	113.52%	85.30%	88.17%	64.34%	110.22%	80.93%	95.58%	86.97%	63.13%
Earnings before Interest and Taxes (EBIT)	-50	-4.87	-25	-9.53	-13	2.03	-15	-6.43	-13	-16	14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-41	4.26	-16	-0.12	-3.67	16	-5.60	2.98	-4.00	-2.38	14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.20	20.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.45
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.25	0.36	0.31	0.65	0.84	1.20	2.05	1.23	1.63	2.59	2.45
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	1.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.28	0.31	0.61	0.82	1.16	1.98	1.22	1.66	2.51	2.09
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	92.01	29.75	41.43	0.00	35.86
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	5.37	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	4.76	12.63	0.00	-1.58	-1.08	-1.13	-1.11	-1.13	-0.76	-0.79	1.89
Long-Term Debt to Equity	0.00	6.52	0.00	-0.69	-0.88	-0.56	-1.11	-1.13	-0.76	-0.79	1.89
Financial Leverage	-1.25	-0.97	-1.01	-0.98	3.24	1.29	-1.01	0.21	0.00	0.27	29.39
Leverage Ratio	6.88	11.17	-0.26	-0.51	-26.24	-23.58	-0.31	-7.83	-4.92	-5.80	-200.10
Compound Leverage Factor	7.54	0.76	-0.28	-0.60	-29.07	-7.10	-0.38	-10.44	-7.37	-8.30	-88.10
Debt to Total Capital	82.64%	92.67%	0.00%	270.97%	1,335.41%	846.13%	1,044.16%	889.20%	-318.38%	-368.79%	65.42%
Short-Term Debt to Total Capital	82.64%	44.88%	0.00%	153.07%	250.71%	426.93%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	47.79%	0.00%	117.90%	1,084.71%	419.20%	1,044.16%	889.20%	-318.38%	-368.79%	65.42%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	17.36%	7.33%	100.00%	-170.97%	-1,235.41%	-746.13%	-944.16%	-789.20%	418.38%	468.79%	34.58%
Debt to EBITDA	-0.64	-1.64	0.00	-0.81	-2.81	-8.57	7.47	5.33	5.64	-4.30	4.31
Net Debt to EBITDA	0.76	0.61	0.00	0.21	0.26	2.04	-2.93	-0.21	0.64	1.46	-6.20
Long-Term Debt to EBITDA	0.00	-0.85	0.00	-0.35	-2.28	-4.25	7.47	5.33	5.64	-4.30	4.31
Debt to NOPAT	-0.67	-1.17	0.00	-0.68	-1.16	-1.07	-1.21	-1.54	-1.57	-1.10	-3.02
Net Debt to NOPAT	0.80	0.43	0.00	0.18	0.11	0.25	0.47	0.06	-0.18	0.37	4.34
Long-Term Debt to NOPAT	0.00	-0.60	0.00	-0.29	-0.94	-0.53	-1.21	-1.54	-1.57	-1.10	-3.02
Altman Z-Score	-4.59	-4.98	-6.66	-7.40	-8.06	-7.88	-8.33	-9.17	-9.74	-9.06	-5.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.26	1.43	1.38	1.28	1.38	1.18	1.70	1.04	1.52	1.41	2.23
Quick Ratio	0.89	1.01	0.21	0.79	0.87	0.82	1.03	0.65	1.01	1.07	1.92
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	57	38	-105	43	-31	21	84	-8.78	-6.03	14	17
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-334,750.00%	-223,300.00%	0.00%
Free Cash Flow to Firm to Interest Expense	62.75	0.00	0.00	0.00	0.00	0.00	161.81	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	37.31	0.00	0.00	0.00	0.00	0.00	-37.59	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	37.31	0.00	0.00	0.00	0.00	0.00	-37.59	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.66	0.81	0.67	0.76	0.65	0.74	0.74	0.77	0.69	0.69
Accounts Receivable Turnover	6.40	6.37	7.91	5.17	11.20	4.89	8.26	7.07	6.20	4.35	4.19
Inventory Turnover	3.46	2.94	2.69	2.66	2.09	3.98	2.85	2.92	3.16	3.96	2.62
Fixed Asset Turnover	36.32	48.88	0.00	0.00	53.05	44.02	0.00	47.72	51.82	54.96	71.55
Accounts Payable Turnover	5.26	3.32	0.00	0.00	4.25	4.54	0.00	5.97	5.46	4.24	4.82
Days Sales Outstanding (DSO)	57.07	57.32	46.16	70.62	32.59	74.62	44.21	51.60	58.83	83.92	87.01
Days Inventory Outstanding (DIO)	105.44	124.12	135.81	137.16	174.78	91.70	127.88	125.09	115.58	92.25	139.55
Days Payable Outstanding (DPO)	69.39	110.07	0.00	0.00	85.91	80.37	0.00	61.13	66.89	86.13	75.66
Cash Conversion Cycle (CCC)	93.12	71.37	181.97	207.78	121.46	85.95	172.09	115.56	107.52	90.04	150.90
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-65	-19	55	-38	-43	-39	-39	-35	-46	-62	-42
Invested Capital Turnover	-12.32	225.60	28.72	-20.01	-4.72	-6.71	23.46	-4.77	-3.80	-3.17	-4.55
Increase / (Decrease) in Invested Capital	-92	-41	87	-50	22	-20	-94	2.67	-2.73	-24	-3.21
Enterprise Value (EV)	-21	82	103	159	211	225	371	212	282	401	387
Market Capitalization	58	106	103	170	215	234	383	214	278	415	454
Book Value per Share	$0.08	$0.03	($8.60)	($0.14)	($0.21)	($0.16)	($0.13)	($0.16)	($0.24)	($0.23)	$0.10
Tangible Book Value per Share	($0.67)	($0.68)	($8.92)	($0.75)	($0.76)	($0.67)	($0.54)	($0.53)	($0.56)	($0.50)	($0.15)
Total Capital	80	71	-1,584	16	3.19	4.10	2.89	4.28	-12	-10	71
Total Debt	66	66	0.00	42	43	35	30	38	38	39	47
Total Long-Term Debt	0.00	34	0.00	18	35	17	30	38	38	39	47
Net Debt	-79	-24	0.00	-11	-3.92	-8.24	-12	-1.47	4.34	-13	-67
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-29	-2.82	33	-3.31	-8.63	-7.15	4.50	-35	0.39	-19	-0.82
Debt-free Net Working Capital (DFNWC)	115	88	33	50	38	36	46	4.80	34	33	113
Net Working Capital (NWC)	50	56	33	26	30	18	46	4.80	34	33	113
Net Nonoperating Expense (NNE)	19	-1.50	8.96	4.87	5.36	0.76	7.53	2.47	11	13	7.40
Net Nonoperating Obligations (NNO)	-79	-24	1,639	-11	-3.92	-8.24	-12	-1.47	4.34	-13	-67
Total Depreciation and Amortization (D&A)	9.42	9.12	9.41	9.41	9.41	14	9.38	9.41	9.37	14	0.31
Debt-free, Cash-free Net Working Capital to Revenue	-12.57%	-0.96%	9.97%	-1.26%	-3.37%	-3.67%	2.40%	-19.89%	0.23%	-11.83%	-0.44%
Debt-free Net Working Capital to Revenue	49.62%	29.97%	9.97%	19.15%	14.81%	18.38%	24.81%	2.75%	20.26%	20.55%	60.87%
Net Working Capital to Revenue	21.29%	19.03%	9.97%	10.01%	11.69%	9.39%	24.81%	2.75%	20.26%	20.55%	60.87%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.28)	($0.04)	$0.00	$0.00	($0.08)	$0.01	($0.09)	($0.04)	($0.10)	($0.10)	$0.03
Adjusted Weighted Average Basic Shares Outstanding	183.88M	182.78M	0.00	0.00	188.31M	187.47M	204.96M	209.71M	210.35M	210.95M	235.50M
Adjusted Diluted Earnings per Share	($0.28)	($0.03)	$0.00	$0.00	($0.08)	$0.01	($0.09)	($0.04)	($0.10)	($0.10)	$0.03
Adjusted Weighted Average Diluted Shares Outstanding	183.88M	182.78M	0.00	0.00	188.31M	187.47M	204.96M	209.71M	210.35M	210.95M	241.60M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	183.96M	184.25M	0.00	0.00	188.39M	209.37M	209.60M	210.29M	218.18M	236.23M	262.64M
Normalized Net Operating Profit after Tax (NOPAT)	-35	-2.55	-18	-6.36	-9.01	0.96	-10	-6.11	-8.75	-10	9.46
Normalized NOPAT Margin	-72.17%	-2.17%	-44.60%	-11.29%	-21.42%	1.71%	-31.94%	-13.99%	-23.39%	-21.54%	16.50%
Pre Tax Income Margin	-113.44%	-0.28%	-67.18%	-19.82%	-34.46%	1.09%	-55.16%	-19.66%	-53.54%	-49.04%	10.66%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-55.63	0.00	0.00	0.00	0.00	0.00	-28.96	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-38.94	0.00	0.00	0.00	0.00	0.00	-20.22	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-55.63	0.00	0.00	0.00	0.00	0.00	-28.96	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-38.94	0.00	0.00	0.00	0.00	0.00	-20.22	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

Akebia Therapeutics reported a standout Q1 2025 with revenue up 75.8% year-over-year, a return to net profitability, and positive free cash flow. High gross and EBITDA margins underpin the operating performance, while a strong cash balance supports ongoing R&D investment. Key considerations remain the negative operating cash flow, dilution from recent equity raises, and elevated leverage on the balance sheet.

Q1 2025 revenue climbed 75.8% YoY to $57.3 million, driven by increased product uptake
Net income of $6.11 million in Q1 2025 versus a $17.9 million loss in Q1 2024
Exceptional gross margin of 86.7% and EBITDA margin of 24.8% in Q1 2025
Generated $16.7 million of free cash flow to the firm in Q1 2025
Cash & equivalents of $113.4 million provide a solid liquidity cushion
Book value per share turned positive at $0.1041, from –$0.13 a year ago
Valuation at 2.09× EV/Revenue and 35.9× EV/EBITDA reflects growth expectations
Operating cash flow remained negative at –$13.6 million in Q1 2025
Raised $65 million of common equity in Q1 2025, diluting existing shareholders
Total liabilities of $285.6 million versus equity of $24.6 million imply high leverage

07/08/25 03:20 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Akebia Therapeutics' Financials

When does Akebia Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Akebia Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Akebia Therapeutics' net income changed over the last 10 years?

Akebia Therapeutics' net income appears to be on an upward trend, with a most recent value of -$69.41 million in 2024, rising from -$37.03 million in 2014. The previous period was -$51.93 million in 2023. See where experts think Akebia Therapeutics is headed by visiting Akebia Therapeutics' forecast page.

What is Akebia Therapeutics' operating income?

Akebia Therapeutics' total operating income in 2024 was -$50.47 million, based on the following breakdown:

Total Gross Profit: $97.00 million
Total Operating Expenses: $147.48 million

How has Akebia Therapeutics' revenue changed over the last 10 years?

Over the last 10 years, Akebia Therapeutics' total revenue changed from $0.00 in 2014 to $160.18 million in 2024, a change of 16,018,000,000.0%.

How much debt does Akebia Therapeutics have?

Akebia Therapeutics' total liabilities were at $269.86 million at the end of 2024, a 0.9% decrease from 2023, and a 3,801.3% increase since 2014.

How much cash does Akebia Therapeutics have?

In the past 10 years, Akebia Therapeutics' cash and equivalents has ranged from $32.78 million in 2014 to $228.70 million in 2020, and is currently $51.87 million as of their latest financial filing in 2024.

How has Akebia Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Akebia Therapeutics' book value per share changed from 5.12 in 2014 to -0.23 in 2024, a change of -104.4%.

Related Companies

This page (NASDAQ:AKBA) was last updated on 7/8/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Financials

Key Financial Trends

Frequently Asked Questions About Akebia Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Financials

Annual Income Statements for Akebia Therapeutics

Quarterly Income Statements for Akebia Therapeutics

Annual Cash Flow Statements for Akebia Therapeutics

Quarterly Cash Flow Statements for Akebia Therapeutics

Annual Balance Sheets for Akebia Therapeutics

Quarterly Balance Sheets for Akebia Therapeutics

Annual Metrics And Ratios for Akebia Therapeutics

Quarterly Metrics And Ratios for Akebia Therapeutics

Key Financial Trends

Frequently Asked Questions About Akebia Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools